FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies
David A. Knorr(Memorial Sloan Kettering Cancer Center), Jeffrey V. Ravetch(Laboratory of Molecular Genetics), David E. Sprott(Claremont Graduate University), Andrew Jones(Guy's and St Thomas' NHS Foundation Trust), R. Bryan Bell(Takara (United States)), Shawn M. Jensen(Providence Portland Medical Center), Carmen Ballesteros‐Merino(Cancer Institute (WIA)), Carlo Bifulco(Providence Health & Services), Rom S. Leidner(Providence Portland Medical Center), Bernard A. Fox(Oregon Health & Science University), Brian Piening(Providence College), Rony Dahan(Weizmann Institute of Science), Ryan Meng(Providence Portland Medical Center), Maria Baez(Rockefeller University)
Cited by 2
Related Papers
The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight
|Science|2019|1.1k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
The role of IgG Fc receptors in antibody-dependent enhancement
|Nature reviews. Immunology|2020|634
Longitudinal multi-omics of host–microbe dynamics in prediabetes
|Nature|2019|620